SEC ownership of Cellectar Biosciences, Inc.

Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001279704.

CIK
0001279704
Symbol
CLRB on Nasdaq
Location
Florham Park, NJ
Parsed ownership evidence
13D/G, 13F, and 3/4/5
Lead holder
Stonepine Capital Management, LLC
13D/G signal
Stonepine Capital Management, LLC
Latest evidence date
07 May 2026

Ownership snapshot

Top shareholders of Cellectar Biosciences, Inc. (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Lead holder
Stonepine Capital Managem...
13D/G signal
Stonepine Capital Managem...
Evidence rows
38
Latest as of
07 May 2026
13D/G 13F 3/4/5 Lead comparable stake: 9.9% 13D/G row: Stonepine Capital Management, LLC Showing first 8 of 38 holder rows. Open remaining rows
Holder Evidence Ownership % Position 12M Net Δ As of
Stonepine Capital Management, LLC
13D/G
9.9%
863,277 shares
$0 04 May 2026
Rosalind Advisors, Inc.
13D/G
5.5%
247,715 shares
$0 31 Dec 2025
INTRACOASTAL CAPITAL, LLC
13D/G
Mitchell P. Kopin
5%
140,101 shares
$0 01 Jul 2025
Orin Hirschman
13D/G
4.9%
$586,444
2,022,221 shares
$0 31 Dec 2024
Hexstone Capital LLC
13D/G
4.9%
$553,293
216,130 shares
+$169,293 31 Dec 2025
Bleichroeder LP
13D/G 13F
Company
4.6%
$760,000
200,000 shares
$0 31 Dec 2025
Laurence W. Lytton
13D/G
LYTTON LAURENCE W
1.6%
$250,788
51,391 shares
$0 30 Jun 2025
ADAR1 Capital Management, LLC
13D/G
0.1%
2,962 shares
$0 30 Jun 2025
Show 30 additional holder rows in the full holder list
Holder Evidence Ownership % Position 12M Net Δ As of
Nantahala Capital Management, LLC
13D/G
0.06%
$5,412
1,109 shares
$0 30 Jun 2025
VANGUARD CAPITAL MANAGEMENT LLC
13F
Company
13F
1.9%
$207,985
81,884 shares
31 Mar 2026
GEODE CAPITAL MANAGEMENT, LLC
13F
Company
13F
1.2%
$134,062
52,778 shares
31 Mar 2026
Sequoia Financial Advisors, LLC
13F
Company
13F
0.43%
$47,879
18,850 shares
31 Mar 2026
VANGUARD FIDUCIARY TRUST CO
13F
Company
13F
0.38%
$42,095
16,573 shares
31 Mar 2026
Warberg Asset Management LLC
13F
Company
13F
0.32%
$35,306
13,900 shares
31 Mar 2026
Riverview Capital Advisers, LLC
13F
Company
13F
0.24%
$50,051
10,384 shares
31 Mar 2026
UBS Group AG
13F
Company
13F
0.22%
$24,504
9,647 shares
31 Mar 2026
BlackRock, Inc.
13F
Company
13F
0.11%
$12,052
4,745 shares
31 Mar 2026
Tower Research Capital LLC (TRC)
13F
Company
13F
0.02%
$2,014
793 shares
31 Mar 2026
Vanguard Global Advisers, LLC
13F
Company
13F
0.01%
$1,430
563 shares
31 Mar 2026
MORGAN STANLEY
13F
Company
13F
0.01%
$1,295
510 shares
31 Mar 2026
TD Waterhouse Canada Inc.
13F
Company
13F
0%
$154
63 shares
31 Mar 2026
SBI Securities Co., Ltd.
13F
Company
13F
0%
$28
11 shares
31 Mar 2026
FMR LLC
13F
Company
13F
0%
$25
10 shares
31 Mar 2026
JONES FINANCIAL COMPANIES LLLP
13F
Company
13F
0%
$8
3 shares
31 Mar 2026
US BANCORP \DE\
13F
Company
13F
0%
$8
3 shares
31 Mar 2026
DANSKE BANK A/S
13F
Company
13F
0%
$5
2 shares
31 Mar 2026
OSAIC HOLDINGS, INC.
13F
Company
13F
0%
$2
1 shares
31 Mar 2026
Jarrod D. Longcor
3/4/5
Chief Operating Officer
mixed-class rows
$58,898
556,600 shares
mixed-class rows
+$24,998 07 May 2026
James V Caruso
3/4/5
Chief Executive Officer, Director
mixed-class rows
$58,515
956,394 shares
mixed-class rows
+$24,998 07 May 2026
Andrei Shustov
3/4/5
Senior Vice President, Medical
mixed-class rows
$15,411
315,038 shares
mixed-class rows
14 Jun 2024
Darrell Shane Lea
3/4/5
Chief Commercial Officer
mixed-class rows
$11,088
299,599 shares
mixed-class rows
14 Jun 2024
Chad J. Kolean
3/4/5
Chief Financial Officer
mixed-class rows
$2,823
301,418 shares
mixed-class rows
02 Jul 2025
John Neis
3/4/5
Director
mixed-class rows
$36
60,010 shares
mixed-class rows
-$732 12 Dec 2025
Dov Elefant
3/4/5
Chief Financial Officer
class O/S missing
422,000 shares
25 Jan 2022
Douglas J. Swirsky
3/4/5
Director
class O/S missing
90,000 shares
14 Feb 2025
Asher Chanan-Khan
3/4/5
Director
class O/S missing
60,000 shares
14 Feb 2025
Frederick W. Driscoll
3/4/5
Director
class O/S missing
60,000 shares
14 Feb 2025
Stefan Loren
3/4/5
Director
class O/S missing
60,000 shares
14 Feb 2025
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Forms 3/4/5 flow

Insider trading overview

Net insider flow leans to buying over the last 12 months. Net value: +$49,265.

Buys
$49,997
Insiders: 2
Sells
$732
Insiders: 1
Net
+$49,265
Shares: +17,162
Window
Last 12 months
4 rolling buckets
Buy value Sell value
Shares: 17,360 Shares: 198
Window (months) Buy shares Sell shares Buy $ Sell $ Net $
0-3 17,360 0 $49,997 $0 +$49,997
3-6 0 198 $0 $732 -$732
6-9 0 0 $0 $0 $0
9-12 0 0 $0 $0 $0

Reporting owners

Insider holders from Forms 3/4/5

Current reporting-owner rows connected to Cellectar Biosciences, Inc.. Open the relationship link for the CIK-to-CIK filing trail.

Rows
11
Lead holder
Jarrod D. Longcor
Net 12M change
+$49,264
Latest report
07 May 2026
Name Relationship Holdings Value Past Year Net Change Change % Valuation Report Date
Jarrod D. Longcor Chief Operating Officer $58,898 +$24,998 +74% Filing P/S 07 May 2026
James V Caruso Chief Executive Officer, Director $58,515 +$24,998 +75% Filing P/S 07 May 2026
Andrei Shustov Senior Vice President, Medical $15,411 Mixed 14 Jun 2024
Darrell Shane Lea Chief Commercial Officer $11,088 Mixed 14 Jun 2024
Chad J. Kolean Chief Financial Officer $2,823 Mixed 02 Jul 2025
John Neis Director $36 -$732 -95% Filing P/S 12 Dec 2025
Stefan Loren Director Mixed 14 Feb 2025
Douglas J. Swirsky Director Mixed 14 Feb 2025
Asher Chanan-Khan Director Mixed 14 Feb 2025
Frederick W. Driscoll Director Mixed 14 Feb 2025
Dov Elefant Chief Financial Officer Mixed 25 Jan 2022

Recent Insider Transactions by Companies or Individuals for Cellectar Biosciences, Inc.

Showing up to 300 most recent insider transactions from the last 12 months.

Insider Symbol Class Transaction % Reported value Reported price Shares Shares owned Date Ownership
Jarrod D. Longcor CLRB Common Stock Purchase 73.7% $24,998 $2.88 8,680 20,451 07 May 2026 Direct
Jarrod D. Longcor CLRB Warrants Purchase 257.6% 26,040 36,149 07 May 2026 Direct
James V Caruso CLRB Common Stock Purchase 74.6% $24,998 $2.88 8,680 20,318 07 May 2026 Direct
James V Caruso CLRB Warrants Purchase 259.5% 26,040 36,076 07 May 2026 Direct
John Neis CLRB Common Stock Sale -95.2% $732 $3.70 -198 10 12 Dec 2025 See Footnote
James V Caruso CLRB Common Stock Purchase 610.5% 10,000 11,638 02 Jul 2025 Direct
James V Caruso CLRB Warrants Purchase 10,000 10,000 02 Jul 2025 Direct
Jarrod D. Longcor CLRB Common Stock Purchase 361.3% 10,000 12,768 02 Jul 2025 Direct
Jarrod D. Longcor CLRB Warrants Purchase 10,000 10,000 02 Jul 2025 Direct
Chad J. Kolean CLRB Common Stock Purchase 352.6% 5,000 6,418 02 Jul 2025 Direct
Chad J. Kolean CLRB Warrants Purchase 5,000 5,000 02 Jul 2025 Direct
An asterisk next to the price means the reported price is likely invalid.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .